Pharmaceutical Firms Faced Manufacturing Talent Shortage
As companies rush to expand domestic facilities, the industry struggles to fill thousands of specialized technical roles.
Updated on Sept. 23, 2026 in Manufacturing
Live Poll
Will pharmaceutical companies successfully overcome manufacturing talent shortages while expanding operations in the U.S.?
Pharmaceutical companies have announced $160 billion in U.S. manufacturing investments but are now facing a severe shortage of skilled technical labor. Firms are competing against the data center sector for talent while trying to meet rapid industry growth.
Why it matters
The workforce crisis threatens the success of major reshoring initiatives as the industry faces an aging labor pool and a limited supply of qualified candidates. This imbalance complicates the rollout of large-scale manufacturing projects across the country.
Biological product manufacturing employs over 46,000 people in the U.S. and has grown 5.1% annually over the last decade. Companies now lack 27% of necessary process engineers and face hiring challenges for 36% of development staff roles.
The players
Eli Lilly
This global pharmaceutical company is investing billions in new U.S. manufacturing capacity to boost its production capabilities.
Bristol Myers Squibb
This biopharmaceutical company is a major player in the development of treatments for serious diseases and is expanding its domestic campus footprint.
The details
Companies are scaling bioprocessing programs and partnering with colleges and trade schools to reskill workers from adjacent industries. Major projects, including a $6.5 billion Eli Lilly site and a $2.3 billion Bristol Myers Squibb campus in Houston, highlight the intensive demand for staff.
Timeline
A BioPlan study identified the workforce crisis in January 2026.
Bristol Myers Squibb announced its Houston project in August 2026.
Eli Lilly broke ground on its Houston facility on September 21, 2026.
The competitive labor war is expected to intensify through 2027 and 2028.
Indiana faces high biomanufacturing hiring needs over the next decade.
Market Landscape
The labor shortage serves as a major bottleneck for the domestic pharmaceutical sector, which has maintained a 5.1% annual growth rate over the past ten years. This competition for specialized talent pits pharmaceutical giants against high-growth sectors like data centers.
The widespread talent deficit may lead to construction delays for new pharmaceutical facilities and increased costs for specialized bioproducts. Consumers and medical patients could see shifts in the availability of new treatments as firms navigate these production hurdles.
The takeaway
The pharmaceutical industrys rapid expansion is colliding with a structural lack of qualified engineers and production staff. Companies that successfully implement deep partnerships with trade schools will likely gain a critical advantage in meeting production targets.
Further reading
For more background on industry trends, visit the Manufacturing section.
Source note: This article includes information reported by Pharma.
Live Poll
Will pharmaceutical companies successfully overcome manufacturing talent shortages while expanding operations in the U.S.?
